9 Oral - Targeting a KRAS neoantigen peptide vaccine to DNGR-1+ dendritic cells

Abstract

Background: Oncogenic point mutations in KRAS drive some of the most aggressive forms of human cancer, including approximately 32% of lung adenocarcinomas, 50% of colorectal cancers and 88% of pancreatic cancers. Despite a pressing clinical need and decades of research there are currently no licensed selective inhibitors of KRAS oncoproteins, although recent development of several KRASG12C selective inhibitors appear highly promising. As an alternative approach, we are pursuing research into the immune response to KRAS mutant proteins. We propose that expansion of a mutant-KRAS specific T cell response using vaccination strategies could provide the specificity and efficacy which pharmacological approaches have so far failed to achieve.